{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:47:47Z","timestamp":1794469667465,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40257-025-00931-1","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:47:24Z","timestamp":1741967244000},"page":"587-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct03131648","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03160885","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03587805","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Bjerreg\u00e5rd","family":"\u00d8land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Gjerum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Maslin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"7","key":"931_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/jdv.15574","volume":"33","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"931_CR2","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/jdv.16892","volume":"34","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD\/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"931_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, Guttman-Yassky E, Calimlim B, Wegzyn C, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89(3):519\u201328.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"931_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, Chiricozzi A. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23(7):575\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"931_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019;81(4):943\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"931_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"931_CR7","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"2","key":"931_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.18176\/jiaci.0641","volume":"32","author":"E Nettis","year":"2022","unstructured":"Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E, et al. Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol. 2022;32(2):124\u201332.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"931_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"931_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","volume":"84","author":"LFM Ariens","year":"2021","unstructured":"Ariens LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"931_CR11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, Elberling J, Skov L, Ibler KS, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"931_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s13555-021-00638-1","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B. Dupilumab with topical corticosteroids provides rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across anatomic regions over 52 weeks. Dermatol Ther (Heidelb). 2022;12(1):223\u201331.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"931_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/DER.0000000000000801","volume":"33","author":"AG Ashbaugh","year":"2022","unstructured":"Ashbaugh AG, Murase EM, Raffi J, Botto N, Murase JE. Characterization of residual facial dermatitis during dupilumab therapy: a retrospective chart review to delineate the potential role of expanded series patch testing. Dermatitis. 2022;33(1):51\u201361.","journal-title":"Dermatitis"},{"issue":"4","key":"931_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1159\/000512890","volume":"237","author":"N Gori","year":"2021","unstructured":"Gori N, Chiricozzi A, Malvaso D, D\u2019Urso DF, Caldarola G, De Simone C, et al. Successful combination of systemic agents for the treatment of atopic dermatitis resistant to dupilumab therapy. Dermatology. 2021;237(4):535\u201341.","journal-title":"Dermatology"},{"issue":"1","key":"931_CR15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2019.06.026","volume":"82","author":"RA Waldman","year":"2020","unstructured":"Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"931_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745\u20139.","journal-title":"Br J Dermatol"},{"issue":"5","key":"931_CR17","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"931_CR18","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1111\/ijd.15871","volume":"61","author":"F Russo","year":"2022","unstructured":"Russo F, Rizzo A, Santi F, Lamberti A, Lazzeri L, Flori ML, et al. A paradoxical head and neck erythema: an adverse event due to dupilumab in adult patients with atopic dermatitis. Int J Dermatol. 2022;61(6):e204\u20136.","journal-title":"Int J Dermatol"},{"issue":"11","key":"931_CR19","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jamadermatol.2019.2613","volume":"155","author":"A Soria","year":"2019","unstructured":"Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Salle D, Barbarot S, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312\u20135.","journal-title":"JAMA Dermatol"},{"issue":"7","key":"931_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","volume":"155","author":"GA Zhu","year":"2019","unstructured":"Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(7):850\u20132.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"931_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/pde.14499","volume":"38","author":"CE Bax","year":"2021","unstructured":"Bax CE, Khurana MC, Treat JR, Castelo-Soccio L, Rubin AI, McMahon PJ. New-onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis. Pediatr Dermatol. 2021;38(2):390\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"931_CR22","volume":"95","author":"L Ambrosio","year":"2024","unstructured":"Ambrosio L, Tolino E, Proietti I, Bernardini N, Skroza N, Potenza C. Dupilumab-associated facial redness not responsive to antifungal therapy successfully treated with tralokinumab. Acta Biomed Ateno Parmense. 2024;95(5): e2024108.","journal-title":"Acta Biomed Ateno Parmense."},{"issue":"2","key":"931_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","volume":"429","author":"B Popovic","year":"2017","unstructured":"Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol. 2017;429(2):208\u201319.","journal-title":"J Mol Biol"},{"issue":"5","key":"931_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100214","volume":"3","author":"MAX Tollenaere","year":"2023","unstructured":"Tollenaere MAX, Molck C, Henderson I, Pollack S, Addis P, Petersen HH, et al. Tralokinumab effectively disrupts the IL-13\/IL-13Ralpha1\/IL-4Ralpha signaling complex but not the IL-13\/IL-13Ralpha2 complex. JID Innov. 2023;3(5): 100214.","journal-title":"JID Innov."},{"issue":"11","key":"931_CR25","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1111\/all.15811","volume":"78","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Guttman-Yassky E, Eichenfield LF, Boguniewicz M, Bieber T, Schneider S, et al. Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition. Allergy. 2023;78(11):2875\u201391.","journal-title":"Allergy"},{"issue":"9","key":"931_CR26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema. Part I: systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"931_CR27","doi-asserted-by":"crossref","unstructured":"AAAAI\/ACAAI JTF Atopic Dermatitis Guideline Panel, Chu DK, Schneider L, Asiniwasis RN, Boguniewicz M, De Benedetto A, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274\u2013312.","DOI":"10.1016\/j.anai.2023.11.009"},{"issue":"2","key":"931_CR28","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43-56.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"931_CR29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.21867","volume":"187","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Merola JF, Silverberg JI, Reich K, Warren RB, Staumont-Salle D, et al. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. Br J Dermatol. 2022;187(6):888\u201399.","journal-title":"Br J Dermatol"},{"issue":"6","key":"931_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, et al. Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials. Am J Clin Dermatol. 2023;24(6):939\u201352.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"931_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"4","key":"931_CR32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40257-022-00702-2","volume":"23","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022;23(4):547\u201359.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"931_CR33","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","volume":"184","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184(3):450\u201363.","journal-title":"Br J Dermatol"},{"issue":"6","key":"931_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","volume":"159","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596\u2013605.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"931_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87(4):815\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"931_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ced\/llad038","volume":"48","author":"AR Schlosser","year":"2023","unstructured":"Schlosser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023;48(5):510\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"931_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ajd.14264","volume":"65","author":"FJ Navarro-Trivino","year":"2024","unstructured":"Navarro-Trivino FJ, Salazar-Nievas M, Sanz-Cabanillas JL, Arjona-Aguilera C. Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: a multicentre study of 12 patients. Australas J Dermatol. 2024;65(3):260\u20135.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"931_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The Eczema Area and Severity Index: a practical guide. Dermatitis. 2022;33(3):187\u201392.","journal-title":"Dermatitis"},{"issue":"3","key":"931_CR39","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"931_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/10920277.2012.10597644","volume":"16","author":"M de Carvalho","year":"2012","unstructured":"de Carvalho M, Marques FJ. Jackknife Euclidean likelihood-based inference for Spearman\u2019s rho. N Am Actuarial J. 2012;16(4):487\u201392.","journal-title":"N Am Actuarial J."},{"key":"931_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis. Use R!","author":"H Wickham","year":"2016","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis. Use R! 2nd ed. Cham: Springer International Publishing; 2016. p. 1.","edition":"2"},{"issue":"10","key":"931_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, Pierce EJ, Rueda MJ, DeLozier AM, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"931_CR43","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/exd.14368","volume":"30","author":"S Ribero","year":"2021","unstructured":"Ribero S, Puglisi B, Giura MT, Viola R, Siliquini N, Quaglino P, et al. Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients. Exp Dermatol. 2021;30(11):1717\u20138.","journal-title":"Exp Dermatol"},{"key":"931_CR44","unstructured":"Dupixent\u00ae. Prescribing information. Sanofi Biotechnology and Regeneron Pharmaceuticals Inc.; 2024. Available from: https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 22 Jan 2025."},{"key":"931_CR45","unstructured":"Dupixent\u00ae. Product information. Sanofi Biotechnology and Regeneron Pharmaceuticals Inc.; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 23 Jan 2025."},{"issue":"1","key":"931_CR46","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41467-024-46540-0","volume":"15","author":"C Bangert","year":"2024","unstructured":"Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M, et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15(1):2839.","journal-title":"Nat Commun"},{"issue":"6","key":"931_CR47","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","volume":"134","author":"JD Hamilton","year":"2014","unstructured":"Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134(6):1293\u2013300.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"931_CR48","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jid.2021.01.022","volume":"141","author":"DS Bakker","year":"2021","unstructured":"Bakker DS, van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM, et al. Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis. J Invest Dermatol. 2021;141(8):1943-53.e13.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"931_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/cells12020239","volume":"12","author":"R Kishi","year":"2023","unstructured":"Kishi R, Toyama S, Tominaga M, Kamata Y, Komiya E, Kaneko T, et al. Effects of dupilumab on itch-related events in atopic dermatitis: implications for assessing treatment efficacy in clinical practice. Cells. 2023;12(2):239.","journal-title":"Cells"},{"issue":"11","key":"931_CR50","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1111\/ijd.17231","volume":"63","author":"S Garcia-Gonzalez","year":"2024","unstructured":"Garcia-Gonzalez S, Villagrasa-Boli P, Bularca E, Moratiel-Pellitero A, Prieto-Torres L. Tralokinumab-related facial redness: a therapeutic challenge. Int J Dermatol. 2024;63(11):1605\u20136.","journal-title":"Int J Dermatol"},{"issue":"6","key":"931_CR51","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, Nahm WK, Pauser S, Da Rosa JC, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(6):1560\u201372.","journal-title":"Allergy"},{"issue":"2","key":"931_CR52","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00931-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00931-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:03:31Z","timestamp":1751619811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00931-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00931-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"9 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ECZTRA 1, ECZTRA 2, and ECZTEND trials were sponsored by LEO Pharma A\/S (Ballerup, Denmark).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Raj Chovatiya has served as an advisor, consultant, speaker, and\/or investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CLn Skin Care, Dermavant, Eli Lilly and Company, EMD Serono, FIDE, Formation Bio, Galderma, Genentech, GSK, Johnson & Johnson, Incyte, LEO Pharma, L\u2019Or\u00e9al, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, and UCB. Raj Chovatiya is an Editorial Board member of the American Journal of Clinical Dermatology. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Simone Ribero received research grants, personal fees, or non-financial support from AbbVie, Almirall, BMS, Galderma, LEO Pharma, Lilly, L\u2019Oreal, Novartis, Pfizer, Pierre Fabre, and Sanofi. Andreas Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, LEO Pharma, L\u2019Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis, and UCB. Chang Ook Park is an investigator for Sanofi, Pfizer, Galderma, Eli Lilly, LEO Pharma, Amgen, AstraZeneca, GSK, Kiniksa Pharmaceuticals, and Teva Pharmaceuticals. Juan Francisco Silvestre has served as an investigator and\/or speaker and\/or advisor for following pharmaceutical companies: AbbVie, Almirall-Hermal, Amgen, AstraZeneca, Eli-Lilly, Galderma, LEO Pharma, Incyte, Novartis, Pfizer, Regeneron, and Sanofi-Genzyme. H. Chih-ho Hong is a researcher, consultant, and\/or advisor for AbbVie, Amgen, Arcutis, Aslan, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Dermavant, Dermira, DS Biopharma, Eli Lilly, Evelo, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, and UCB. Julien Seneschal has served as an investigator, speaker, and\/or advisor for Abbvie, Almirall, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi\u2010Genzyme. Hidehisa Saeki received lecture fees and\/or clinical research funding and\/or grant donations from Mitsubishi Tanabe Pharma Corporation, Taiho Pharmaceutical Co., Ltd., AbbVie GK, Sanofi K.K., Torii Pharmaceutical Co. Ltd., Maruho Co., Ltd., Japan Tobacco Inc., Eli Lilly Japan K.K., LEO Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Novartis Pharma K.K, Pfizer Japan Inc., Amgen Inc., Eisai Co., Ltd., and Tokiwa Pharmaceutical Co., Ltd. Jacob P. Thyssen is an employee of LEO Pharma and holds stock options, and served previously as an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, Pfizer, Regeneron, and Sanofi-Genzyme; a speaker for AbbVie, Almirall, Eli Lilly & Co, Pfizer, Regeneron, and Sanofi Genzyme; and received research grants from Pfizer, Regeneron, and Sanofi Genzyme. Christian Bjerreg\u00e5rd \u00d8land is a former employee of LEO Pharma A\/S. Le Gjerum and Douglas Maslin are employees and shareholders of LEO Pharma A\/S. Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB, has served as a scientific adviser (received honoraria) for AbbVie, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte, IQVIA, Janssen, LEO Pharma, Lipidio, Merck, Novartis, Oruka, Paragon, Pfizer, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, UCB Pharma, and Union, has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, and UCB Pharma, and owns stock in Lipidio and Oruka.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The ECZTRA 1, ECZTRA 2, and ECZTEND trials were sponsored by LEO Pharma A\/S (Ballerup, Denmark) and conducted in accordance with the ethical principles derived from international guidelines including the Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines and in compliance with International Council for Harmonisation guidelines for Good Clinical Practice. The clinical trials were approved by institutional review boards or ethics committees at each study site. These trials followed the Consolidated Standards of Reporting Trials reporting guideline.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data will be made available, upon request to the study sponsor, following review by the external patient and the scientific review board.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: all authors contributed equally; investigation: all authors contributed equally; data curation: CB\u00d8; formal analysis: CB\u00d8 (lead); methodology: CB\u00d8 (equal), DM (equal); writing: all authors contributed equally; review\/editing: all authors contributed equally. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}